Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
This study is currently recruiting participants.
Verified March 2013 by Merck KGaA
Study NCT01075828
Information provided by Merck KGaA
First Received on February 24, 2010.
Last Updated on March 1, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
